Pegfilgrastim injection

Pegfilgrastim injection

Form: Injection

Strength: 6 mg per single-use syringe

Reference Brands: Neulasta, Pelgraz(US)

Category: Blood Disorder

Pegfilgrastim injection, marketed as Neulasta and biosimilars like Pelgraz, is approved in the US by the FDA and in the EU via EMA for preventing chemotherapy-induced neutropenia. Regulatory approval requires a comprehensive dossier including biosimilarity data, clinical efficacy, safety, manufacturing quality, and pharmacovigilance plans. In the US, FDA review involves detailed assessment of the biosimilar complex, while the EMA ensures compliance with regional standards. For guidance on dossier preparation, regulatory pathways, and successful market access strategies, visit PharmaTradz. Ensuring compliance with regional regulations is essential for the safe, effective, and timely approval of pegfilgrastim injection worldwide, supporting patient safety during cancer chemotherapy.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Anti-Inhibitor Coagulant Complex (AICC) Lyophilized Powder

Strength: 500 units, 1000 units, and 2500 units

Form: Lyophilized Powder (Reconstituted for IV infusion)

Reference Brands: FEIBA(US)

View Details Get Enquiry
Prothrombin Complex Concentrate (PCC) injection

Strength: 250 IU to 300 IU

Form: Injection

Reference Brands: Kcentra (4-factor PCC), Bebulin VH (3-factor PCC)(US)

View Details Get Enquiry
Mesna Injection

Strength: 100 mg/mL

Form: Injection

Reference Brands: Mesnex(US)

View Details Get Enquiry
Leucovorin tablets/Capsule

Strength: 15 mg, 50 mg

Form: Tablet/Capsules

Reference Brands: Folvite(US & EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.